The failure of CervoMed’s much-anticipated RewinD-LB Phase IIb study of neflamapimodin in patients with dementia with Lewy bodies (DLB) has left investors disappointed and the company scratching its head.
What Was Behind CervoMed’s Lewy Body Disappointment?
Shares in the CNS disease-focused biotech crashed by nearly 80% after its lead product, neflamapimodin, failed in a Phase IIb study in Lewy body dementia. Investors are pondering what went wrong.

More from Clinical Trials
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
More from Therapy Areas
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.